Paracrine growth factor–mediated resistance to TKI has previously been studied (31, 32) and, in some cases, may be attributed to tumor-intrinsic NRG1 overexpression invoked by oncogenic NRG1 genomic fusions (33, 34). This evidence concerns the gene NRG1 and neoplasm.